Ozmosi | Narlaprevir Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Narlaprevir

Alternative Names: narlaprevir
Clinical Status: Inactive
Latest Update: 2023-09-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: HCV-NS3/4A Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Russia

Approved Indications: None

Known Adverse Events: None

Company: R-Pharm
Company Location: Europe
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Hepatitis A|Hepatitis C, Chronic

Phase 2: Hepatitis C, Chronic|Hepatitis A

Phase 1: Liver Cirrhosis|Coinfection|Cross Infection|Hepatitis C, Chronic

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT03537404

 CJ05013019

P1

Completed

Hepatitis C, Chronic|Cross Infection|Coinfection

2017-06-24

2019-03-22

NCT03832426

 CJ05013007

P1

Completed

Liver Cirrhosis

2014-10-24

2019-03-22

NCT01081158

 Protocol No. P04695

P1

Completed

Hepatitis C, Chronic

2008-08-01

2022-05-04

NCT04246723

 CJ05013053

P2

Completed

Hepatitis A|Hepatitis C, Chronic

2020-04-08

43%

2022-11-01

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT03485846

 CJ05013046

P2

Completed

Hepatitis A|Hepatitis C, Chronic

2018-08-29

26%

2019-03-22

Treatments

NCT03833362

 PIONEER

P3

Completed

Hepatitis A|Hepatitis C, Chronic

2016-03-23

2019-03-22

NCT00689390

 P05063

P3

Terminated

Hepatitis A|Hepatitis C, Chronic

2014-10-13

2022-05-04

Primary Endpoints|Treatments

Recent News Events

Date

Type

Title

09/01/2023

PubMed

 The anti-SARS-CoV-2 activity of novel 9, 10-dihydrophenanthrene derivatives: an insight into molecular docking, ADMET analysis, and molecular dynamics simulation.

04/28/2023

PubMed

 Recent Advances in Covalent Drug Discovery.

10/12/2022

PubMed

 [Comparative evaluation of the effectiveness of narlaprevir in the composition of interferon and interferon-free treatment regimens for patients with chronic hepatitis C].

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions